Resveratrol: Benefits, Forms, Dosing, and Side Effects

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Health Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

Resveratrol (3,5,4'-trihydroxystilbene) is a naturally occurring stilbenoid polyphenol with the chemical formula C14H12O3 [1][2]. It functions as a phytoalexin — a compound plants produce in response to stress, injury, or pathogen attack to defend against fungal infections and environmental damage [1][3]. Resveratrol is found in the skins of red grapes, grape seeds, purple grape juice, red wine, peanuts, blueberries, cranberries, and in particularly high concentrations in the roots of Japanese knotweed (Polygonum cuspidatum), which is the most common source for supplements [2][4].

Resveratrol gained widespread attention in the early 1990s following the popularization of the "French Paradox" — the observation that the French population had relatively low rates of cardiovascular disease despite a diet high in saturated fat, attributed in part to moderate red wine consumption [1][5]. A landmark 2003 study from David Sinclair's laboratory at Harvard Medical School demonstrated that resveratrol activates sirtuin proteins, extending lifespan in yeast cells by up to 70% [1][6]. A subsequent 2006 study showed that resveratrol extended lifespan by approximately 30% in mice fed a high-calorie diet [7]. These findings triggered intense scientific interest and a supplement boom.

However, the initial excitement has been tempered by subsequent research. Clinical trials in humans have produced mixed and often disappointing results for many of the benefits suggested by animal and laboratory studies [2][4]. Resveratrol's oral bioavailability is extremely low — less than 1% to approximately 5% of the parent compound reaches systemic circulation due to extensive first-pass metabolism in the gut and liver [8][9]. Although 70-80% of a dose is absorbed from the gastrointestinal tract, it is rapidly converted to glucuronide and sulfate conjugates, with the parent compound having a plasma half-life of only 9-14 minutes in humans [8][10][11].

Despite promising preclinical data, resveratrol supplementation has not been shown to offer the cardiovascular benefits associated with moderate alcohol consumption [2][12]. The compound remains widely researched, with many clinical trials underway, but definitive proof of major clinical benefit in humans remains elusive for most claimed applications.

Forms and Bioavailability

Isomeric Forms

Resveratrol exists in two geometric isomeric forms: trans-resveratrol and cis-resveratrol. Each contains the same atoms but differs in the spatial orientation around the central double bond [2][1].

• Trans-resveratrol is the naturally predominant form, the most commercially available, and the most extensively researched. It is more thermodynamically stable and more biologically active than the cis form [1][2][13].
• Cis-resveratrol can result from photo- or thermal-induced isomerization of the trans form. It shares some biological activities with trans-resveratrol but has been far less studied [1][13].

Either form can exist as a free compound or attached to a glucose molecule as a glycoside (known as resveratrol glucoside or piceid). In grapes and grape juice, piceid is the predominant form, often present at concentrations 4- to 10-fold higher than free resveratrol [14]. Upon ingestion, piceid undergoes hydrolysis in the gastrointestinal tract, primarily by gut microbiota such as Bifidobacterium infantis, converting it to free resveratrol for absorption [14].

Physically, trans-resveratrol appears as a white to off-white crystalline powder with a melting point of 253-255 degrees Celsius [1]. Resveratrol itself is white, but many resveratrol-containing supplements appear brownish due to other plant compounds present in the extract [2]. The stability of resveratrol is influenced by environmental factors — exposure to UV light or elevated temperatures promotes isomerization from the trans to the cis form. Under alkaline conditions (pH > 8), rapid cis-trans isomerization occurs, whereas the compound remains stable in acidic to neutral pH ranges (pH 2-8) [1].

Sources of Supplemental Resveratrol

Supplements derive resveratrol from several sources, each containing varying amounts of resveratrol alongside other plant chemicals [2]:

• Japanese knotweed (Polygonum cuspidatum) extract: The most common supplement source. Knotweed originated in Japan and China but became invasive in the US after introduction in the late 1800s. Extract from the roots is typically sourced from China, though Canadian sources also exist. Labels rarely indicate country of origin [2]. Resveratrol is also found in the roots of a South American shrub (Senna quinquangulata) [2].
• Red grape skin extract: Contains resveratrol along with other grape polyphenols.
• Grape seed extract (GSE): Contains resveratrol plus proanthocyanidins.
• Grape pomace extract (GPE): Made from pressed grape skins, seeds, and stems.
• Red wine extract: Contains relatively low resveratrol (approximately 1-2 mg of trans-resveratrol per bottle of red wine) alongside hundreds of other polyphenolic compounds [15].

Bioavailability Challenges

Resveratrol faces severe bioavailability limitations that are central to understanding its clinical profile [8][9]:

Absorption: Resveratrol is rapidly absorbed from the gastrointestinal tract, with studies indicating 70-80% of the dose is absorbed via passive diffusion in the intestine [8].

First-pass metabolism: Despite high absorption, the oral bioavailability of the parent compound is less than 1% to approximately 5%, due to extensive presystemic metabolism. Resveratrol undergoes rapid phase II conjugation (glucuronidation and sulfation) in the gut wall and liver. Over 90% of absorbed resveratrol is converted to metabolites within hours of oral administration [8][9][16].

Key metabolites: The primary metabolites include resveratrol-3-O-glucuronide (formed by UGT1A1 and UGT1A3), resveratrol-4'-O-glucuronide (formed by UGT1A9), and resveratrol-3-O-sulfate (formed by SULT1A1). Some of these metabolites retain partial bioactivity comparable to the parent compound in antioxidant, anti-inflammatory, and estrogenic assays [16]. In addition, gut microbiota reduce resveratrol to dihydroresveratrol, and cytochrome P450 enzyme CYP1B1 converts it to piceatannol [16].

Peak plasma concentration: Reached within 30-60 minutes after ingestion [8].

Half-life: The parent resveratrol has a very short plasma half-life of approximately 9-14 minutes. However, its major metabolites persist longer, with half-lives extending to several hours [10][11].

Protein binding: Approximately 98% of circulating resveratrol is bound to plasma proteins such as albumin [17].

Tissue distribution: Higher concentrations accumulate in the liver, kidney, and heart compared to plasma levels. Resveratrol is lipophilic and theoretically capable of crossing the blood-brain barrier, but penetration into the central nervous system is limited by low systemic exposure and rapid biotransformation. Metabolites (resveratrol-3-glucuronide and resveratrol-3-sulfate) have been detected in cerebrospinal fluid following oral administration [17][18].

Enterohepatic recirculation: Conjugated metabolites undergo biliary excretion followed by reabsorption in the intestines, which extends overall systemic exposure. Elimination occurs predominantly through fecal excretion (up to 98% in some animal models), with urinary excretion accounting for a smaller portion as metabolites [10][11].

Dose-dependent kinetics: At higher doses, metabolic pathways become saturated, resulting in nonlinear increases in exposure [9][19].

Interspecies differences: Phase II conjugation occurs more slowly in rodents compared to humans, leading to higher plasma levels and prolonged half-lives of resveratrol in mice and rats. This difference can affect the translation of preclinical findings to human applications [16].

Strategies to Improve Bioavailability

Several approaches have been explored to address resveratrol's poor bioavailability:

• Micronized formulations (e.g., SRT501): Reduce particle size to less than 5 micrometers, resulting in a 3- to 4-fold increase in plasma concentration and area under the curve (AUC) compared to unprocessed resveratrol [20]. Note: SRT501 is an experimental formulation not available as a supplement, and a clinical trial using it was halted due to kidney damage in patients with multiple myeloma (see Safety section) [2][21].
• Lipid-based carriers and nanoformulations: Can significantly improve oral bioavailability by mitigating first-pass effects [9][19].
• Co-ingestion with fats: The food matrix affects absorption, with co-ingestion of fats enhancing bioavailability by improving solubility [9][19].
• Sublingual/buccal delivery: A case study found that transbuccal delivery (via mucoadhesive film) resulted in over 15 times higher fraction of resveratrol detected in blood compared to oral ingestion (0.61% vs 0.04%), suggesting potentially superior bioavailability via the oral mucosa route [22].
• Liposomal resveratrol: Advanced delivery systems achieving 3-8 times higher systemic exposure compared to conventional forms [23].
• Co-administration with piperine: Some formulations include piperine (black pepper extract) to inhibit glucuronidation and improve bioavailability [1].

Labeling Caution

Some products label their resveratrol content in micrograms (mcg) rather than milligrams (mg). Since there are 1,000 micrograms in 1 milligram, a product labeled as containing 100 mcg per pill would require 1,000 pills to achieve a 100 mg dose [2].

Related Compounds

Pterostilbene: A dimethylated derivative of resveratrol found in grapes, blueberries, and heartwood (Pterocarpus marsupium). Due to its greater lipophilicity, pterostilbene exhibits significantly improved oral bioavailability — approximately 80% versus approximately 20% for resveratrol — and has a longer half-life of about 105 minutes compared to resveratrol's 14 minutes [24][25]. However, many of its proposed benefits (reducing inflammation, improving cognition and memory, lowering blood sugar and cholesterol) have only been demonstrated in laboratory and animal studies. Critically, a human study found that a daily dose of either 100 mg or 250 mg of pterostilbene (pTeroPure, by Chromadex, which funded the study) taken for 6-8 weeks significantly increased total and LDL cholesterol in people with high cholesterol (200 mg/dL or above), although the higher dose resulted in a modest decrease in systolic and diastolic blood pressure [26]. A separately published safety analysis using the same study data found no other adverse effects and concluded pterostilbene was safe up to 250 mg [27].

Piceatannol: A tetra-hydroxylated stilbenoid derivative found in grapes and especially abundant in passion fruit seeds. It exhibits enhanced biological potency relative to resveratrol, notably as a more effective SIRT1 activator, with superior antioxidant activity in radical-quenching assays such as DPPH and ABTS [28][29].

Piceid: The predominant glycosylated form of resveratrol in grape skins and wine. In red wines, total stilbene levels average around 4-5 mg/L, where piceid accounts for the majority, often exceeding free resveratrol by 5- to 20-fold. Upon ingestion, piceid is hydrolyzed to resveratrol by gut microbiota [14][30].

Evidence for Health Benefits

Cardiovascular and Blood Pressure Effects

Resveratrol has been investigated for cardiovascular protection through its effects on endothelial function, blood pressure, and lipid profiles. However, results in humans have been largely disappointing despite promising animal data.

Endothelial function — modest improvement: Resveratrol enhances endothelial nitric oxide (NO) production by upregulating endothelial nitric oxide synthase (eNOS) and reducing oxidative stress, improving vasodilation [31]. A study in people with metabolic syndrome found that 100 mg of resveratrol daily for three months increased flow-mediated dilation by 5% [32]. However, the same study showed no significant effect on blood pressure, insulin resistance, lipid profiles, or inflammatory markers [32].

Blood pressure — inconsistent evidence: A 2014 meta-analysis of randomized controlled trials (n=247) receiving doses above 150 mg daily reported significant reductions in systolic blood pressure averaging 2-5 mmHg, particularly at higher doses [33]. However, broader reviews indicate inconsistent effects across human trials, with benefits more pronounced in hypertensive or dyslipidemic subgroups [33]. A 2023 systematic review noted limited but positive impacts on endothelial function and cardiac remodeling in patients with hypertension, though larger trials are needed [34]. Several individual trials found no blood pressure benefit:

• A study in 41 overweight/obese adults without diabetes (average age 61) found that 150 mg/day of trans-resveratrol (resVida, DSM Nutrition, 99.9% pure) for 6 months did not improve blood pressure or body composition. DSM provided the capsules but did not fund the study [35].
• In 179 men and women with type 2 diabetes (average age 65, most on metformin), neither 40 mg nor 500 mg daily of trans-resveratrol (Biotivia Bioceuticals) improved blood pressure compared to placebo [36].
• In obese men, 1,500 mg/day of trans-resveratrol (three 500 mg tablets) for 4 weeks had no effect on blood pressure or lipid oxidation rates [37].
• In middle-aged men with metabolic syndrome, neither 150 mg nor 1,000 mg daily (purity >98%) for 4 months reduced blood pressure, inflammation, or body fat [38].

Lipid effects — potentially harmful at higher doses: Several studies have found that higher doses of resveratrol may worsen cholesterol levels:

• The Danish study among middle-aged men with metabolic syndrome found that 1,000 mg/day for 4 months modestly increased total and LDL cholesterol and worsened fructosamine (a blood sugar marker). The lower dose (150 mg/day) did not show this effect but also showed no benefits [38].
• A study among 120 healthy older adults (average age 72) found that 700 mg/day of resveratrol (NOW Foods) combined with 100 U/day (10 mg/day) of TA-65 (T.A. Sciences) significantly elevated total cholesterol (+25.3 mg/dL) and LDL cholesterol (+17.4 mg/dL) after 3 months, resulting in premature termination of the treatment [39].
• These findings are consistent with a laboratory study in which resveratrol increased atherosclerosis in animals fed a high-fat diet [40].

One study suggested that a combination of resveratrol and grape seed extract may help lower LDL cholesterol and improve inflammation markers, but the researchers warned that high daily doses (hundreds of milligrams to grams) could inhibit enzymes important for the metabolism of statins and other cardiovascular drugs [41].

Gut-liver axis and lipids: Research from 2024-2025 has explored resveratrol's role in modulating the gut-liver axis to address dyslipidemia. In high-fat diet animal models, resveratrol preserved gut mucosal integrity, reduced hepatic oxidative stress, and improved lipid profiles by altering microbiota composition and enhancing bile acid metabolism [42].

Metabolic Health: Blood Sugar, Insulin Resistance, and Obesity

Calorie restriction mimicry: A 30-day study of 150 mg/day of trans-resveratrol (resVida, 99% pure) in obese men showed it mimicked the metabolic effects of a calorie-restricted diet. While it did not affect weight, it resulted in lower systolic blood pressure, improved liver function, and significantly lower triglyceride levels, with indications of improved insulin sensitivity [43].

Blood sugar and insulin — mostly negative results in humans:

• In 41 overweight/obese adults without diabetes, 150 mg/day for 6 months did not improve insulin sensitivity, although HbA1c was modestly lower (35.8 vs 37.6 mmol/mol) in the resveratrol group after adjusting for baseline differences [35].
• In 179 men and women with type 2 diabetes (average age 65, most on metformin), neither 40 mg nor 500 mg daily improved fasting glucose, HbA1c, insulin resistance, CRP, or total cholesterol compared to placebo. The researchers noted that studies finding resveratrol improves glucose control in diabetes tended to involve younger participants and theorized resveratrol may be less helpful in people who have had diabetes for longer periods [36].
• The Danish metabolic syndrome study found no improvement in glucose measures at either 150 mg or 1,000 mg/day; the higher dose actually worsened fructosamine [38].

Meta-analysis data: A 2021 meta-analysis of randomized controlled trials indicated that resveratrol at doses around 500 mg/day significantly reduces HbA1c levels by approximately 0.5% in patients with type 2 diabetes, alongside improvements in fasting glucose and insulin resistance indices [44]. An updated 2022 analysis confirmed these glycemic benefits with dose-dependent effects [45]. These meta-analytic findings conflict with several individual negative trials, suggesting benefit may be limited to specific subpopulations.

Mechanism of action on glucose: Resveratrol activates AMP-activated protein kinase (AMPK), which promotes the translocation of glucose transporter type 4 (GLUT4) to the cell membrane, enhancing glucose uptake in insulin-resistant tissues such as skeletal muscle [46]. It also protects pancreatic beta-cells from oxidative stress, modulates adipokine profiles (decreasing leptin, increasing adiponectin), and activates SIRT1, influencing metabolic gene expression [47][48].

Obesity and body weight: Resveratrol supplementation has not been shown to reduce body weight in human trials. The calorie-restriction mimicry study did not affect weight despite metabolic improvements [43]. In the postmenopausal cognitive replication study, participants taking resveratrol had similar increases in weight and body fat as those on placebo [49]. Emerging 2025 preclinical data suggest resveratrol may influence gut microbiota to support anti-obesity effects, with 5-10% body weight reduction in high-fat diet animal models through enhanced microbial diversity and short-chain fatty acid production [50].

Renal function: A 2023 meta-analysis of 32 randomized controlled trials found that resveratrol supplementation significantly decreased blood urea nitrogen (weighted mean difference -0.84 mg/dL; 95% CI -1.48 to -0.20), creatinine levels (-1.90 micromol/L; 95% CI -3.59 to -0.21), and increased glomerular filtration rate (+7.58 mL/min/1.73 m2; 95% CI 5.25-9.91). Effects were more pronounced in diabetic subgroups, shorter durations, or lower doses for some parameters. This provides low certainty evidence of mild renal protective effects in adults [51].

Cognitive Function and Brain Health

Memory improvement in overweight older adults: A study in Germany involving overweight but healthy individuals (ages 50-75) found that 26 weeks of resveratrol (200 mg with 320 mg of quercetin daily, divided into two doses taken with meals) improved glucose metabolism, memory performance, and hippocampal activity. Participants receiving resveratrol retained significantly more words 30 minutes after hearing them. Other memory measures (recognition, learning ability) also improved but by about the same amount as the placebo group [52].

Failed replication: A subsequent study using the identical dose and duration of resveratrol and quercetin did not improve memory or affect hippocampal activity in older, overweight adults. Those taking resveratrol had similar increases in weight, body fat, and fasting glucose as the placebo group. The researchers could not explain the different results but suggested seasonal changes during the study may have affected participants' diets and activity levels (which decreased during the study) [49].

Cognitive benefits in postmenopausal women: A one-year study in 129 healthy postmenopausal women in Australia (average age 64) found that 75 mg of trans-resveratrol taken twice daily modestly improved overall cognitive performance compared to placebo. The improvement was driven by small increases in processing speed and cognitive flexibility, but there were no significant differences in episodic, verbal, or working memory or language. Blood flow velocity in the brain was little changed in the resveratrol group, although it was reported as "significantly improved" relative to the placebo group in which flow decreased [53].

Cerebrovascular effects: In a double-blind, placebo-controlled crossover study, single oral doses of 250 mg and 500 mg trans-resveratrol increased cerebral blood flow during cognitive tasks in healthy adults, with dose-dependent enhancements in total hemoglobin concentrations and deoxyhemoglobin changes indicative of improved oxygen extraction [54]. Chronic low-dose supplementation (150 mg/day) has also demonstrated improvements in resting cerebral blood flow and cerebrovascular responsiveness in postmenopausal women [55]. A 2025 study found that acute supplementation with 250 mg resveratrol improved neurovascular coupling in young adults after one night of restricted sleep (4 hours) [56].

Alzheimer's disease: A one-year study among men and women with mild to moderate Alzheimer's disease found that a biomarker (Abeta40) that typically decreases with disease progression remained stable in people given large doses of resveratrol (starting at 500 mg/day, increasing to 2,000 mg/day), while it decreased in the placebo group. There were no significant effects on other biomarkers, and cognitive functioning decreased in both groups — slightly less in the resveratrol group, but this was not statistically significant. Brain volume loss was actually greater in the resveratrol group but was not associated with cognitive decline and has been seen in studies of other potential treatments. The researchers cautioned that the findings are preliminary and do not prove resveratrol is beneficial in Alzheimer's disease; further research is required [57]. In preclinical models, resveratrol promotes clearance of amyloid-beta peptides via autophagy activation, inhibits tau hyperphosphorylation, and preserves synaptic function [58][59]. A 2023 meta-analysis indicated enhancements in cognitive function, including trends toward better Mini-Mental State Examination (MMSE) scores [60].

Neuroprotection beyond Alzheimer's: In Parkinson's disease models, resveratrol protects dopaminergic neurons by preserving dopamine levels, reducing oxidative stress, and inhibiting microglial activation. In Huntington's disease models, it attenuates mutant huntingtin toxicity and improves motor coordination. Clinical translation for both conditions remains preliminary [61][62].

SIRT1 Activation and Longevity

Resveratrol has been found to either directly or indirectly activate the SIRT1 gene — sometimes referred to as the "longevity gene" — associated with cellular metabolism, cellular repair, and lifespan in animals [6][63]. SIRT1 is an NAD+-dependent deacetylase that deacetylates peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), stimulating mitochondrial biogenesis. Resveratrol activates SIRT1 by lowering its Michaelis constant for both acetylated substrates and NAD+, enhancing deacetylation activity at low micromolar concentrations [64].

Additionally, resveratrol phosphorylates AMP-activated protein kinase (AMPK) through mechanisms involving increased cytosolic calcium and activation of calcium/calmodulin-dependent protein kinase kinase-beta. AMPK activation inhibits anabolic processes and stimulates catabolism, enhancing mitochondrial function [46].

Antioxidant mechanisms: Resveratrol upregulates the Nrf2 pathway (a master regulator of cellular defense against oxidative stress), promoting increased expression of heme oxygenase-1 and NAD(P)H quinone dehydrogenase 1. It also directly scavenges reactive oxygen species (ROS) and inhibits the NF-kappaB inflammatory pathway [65][66].

Animal lifespan data: In mice made obese with an extremely high-fat diet, those given resveratrol lived an average of 15% longer, showed increased insulin sensitivity, and demonstrated improved motor function [7]. Earlier studies showed lifespan extension in yeast (up to 70%), nematodes, and fruit flies (20-30%) [6][67][68]. Whether normally fed mice also show lifespan extension from resveratrol remains unanswered [2].

Key controversies: The claim that resveratrol directly activates SIRT1 has been challenged. A 2005 study by Kaeberlein and colleagues argued that resveratrol's effects in yeast were indirect rather than via allosteric activation [1]. Further controversy arose in 2012 when over 20 studies by researcher Dipak Das were retracted due to image manipulation and data fabrication related to resveratrol's cardioprotective effects [1]. A subsequent 2013 study provided additional evidence supporting SIRT1 activation [64], but the field remains contentious.

Human aging data: A study among healthy older adults showed that taking 700 mg of resveratrol and 100 U (10 mg) of TA-65 daily for 5 months did not significantly affect a surrogate marker of biological age (ProBNPage, calculated from levels of a protein marker for heart stress) compared to baseline [39]. Reviews from 2024-2025 highlight improvements in some senescence markers, such as reduced expression of p16 and p21 in peripheral blood mononuclear cells following oral supplementation, suggesting possible delayed cellular aging. However, no human data demonstrate lifespan extension, and achieving effective human doses equivalent to those in animal models (200-400 mg/kg in mice) exceeds safe oral bioavailability [69][70].

Hormetic dose-response: Resveratrol's pharmacodynamic effects often follow a hormetic dose-response curve, where low doses (typically 1-10 micromolar in vitro) elicit beneficial stimulatory responses through adaptive stress pathways, while high doses (>50 micromolar) may inhibit these effects or induce toxicity by overwhelming cellular defenses. This biphasic pattern is observed across models affecting cell survival and antioxidant enzyme induction [71].

Bone Health

An analysis of data from 10 studies involving 698 participants found that taking resveratrol (dose range: 8 to 1,500 mg daily) for 1-12 months did not significantly affect bone mineral density or blood levels of bone biomarkers compared to placebo, regardless of dose, duration, or health status at baseline [72].

One of the included studies, involving 117 postmenopausal women with osteopenia in Australia, showed that 75 mg of resveratrol (Veri-te resveratrol by Evolva SA, which partially funded the study) twice daily for 12 months only very slightly reduced the decline in bone mineral density in the lumbar spine and femur compared to placebo. It did not affect whole-body bone mineral density or 10-year fracture risk [73].

Menopause Symptoms

Further analyses of the postmenopausal cognitive study (75 mg trans-resveratrol twice daily for one year) showed modest benefits relative to placebo for self-reported muscle and joint pain, sweating and flushing, and overall "well-being" (based on pain, mood, and quality of life). Resveratrol did not improve urinary symptoms or vaginal dryness [74].

Migraine

Due to its mild estrogenic activity and potential to improve endothelial function, resveratrol has been proposed for hormone-related migraine in women. A study in Australia among 62 women with menstrual migraine (average age 37, migraine occurring within three days of menstruation onset during three previous cycles) found that 75 mg of trans-resveratrol (Veri-te Resveratrol by Evolva SA) taken twice daily for three months did not reduce the total number of hormonal migraine days, lessen migraine pain, or improve quality of life during menstruation compared to placebo [75].

Age-Related Macular Degeneration (AMD)

Very preliminary evidence suggests resveratrol could be helpful for AMD. A laboratory study found that resveratrol inhibited the production of vascular endothelial growth factors (VEGF) — the overexpression of which worsens AMD — in human retinal cells. VEGF is also the target of anti-VEGF drugs such as Lucentis, Eylea, and Avastin, which are injected directly into the eye [76].

There have been a few case reports of people with AMD experiencing improvement or slower progression while taking one capsule of a resveratrol formulation (providing 100 mg of trans-resveratrol from Polygonum cuspidatum, plus rice bran phytate, quercetin, chlorogenic acid, green tea extract, and 1,000 IU of vitamin D) daily. Modest improvements included reduction of edema and excessive blood vessel growth in the eye and increased macular pigment volume, reported over periods ranging from six weeks to three years [77][78][79]. One small study among healthy adults found that a single capsule of the same formulation increased choroidal thickness (which may decrease in AMD) one hour after ingestion, possibly by increasing blood flow to the eye, compared to placebo [80].

However, no randomized, placebo-controlled studies on the effects of resveratrol in people with AMD have been conducted.

Anti-Viral Effects and COVID-19

In laboratory studies, resveratrol has been shown to have anti-viral effects, inhibiting the protein production and gene expression of viruses including influenza A and Epstein-Barr [81]. A study among 100 men and women with mild COVID-19 found that those given resveratrol (Vita-Age, >98% pure trans-resveratrol from Polygonum cuspidatum; 500 mg capsules, two capsules four times per day for at least 7 days, up to 15 days if symptoms persisted) within seven days of symptom onset tended to show lower incidences of hospitalization, COVID-related ER visits, and COVID-related pneumonia compared to placebo. However, these differences were not statistically significant, and the study may have been too small to detect meaningful differences. All participants also received a single high dose (100,000 IU) of vitamin D [82]. There is no evidence that resveratrol supplementation can prevent COVID-19.

Cancer

Although there are numerous animal and laboratory studies on resveratrol's effects on certain cancers, very little research exists in people. In preclinical models, resveratrol induces cell cycle arrest primarily by activating the tumor suppressor protein p53, promotes apoptosis by downregulating anti-apoptotic proteins (Bcl-2) and upregulating pro-apoptotic factors (Bax and caspases), and inhibits angiogenesis by suppressing VEGF expression. These effects have been observed across diverse cancer types including breast, colon, and prostate cancers, with IC50 values typically ranging from 10-50 micromolar [83].

In animal studies, resveratrol shows reduced tumor volume and incidence in xenograft models when administered at 10-50 mg/kg. It also synergizes with chemotherapeutic agents such as doxorubicin, enhancing cytotoxicity and overcoming multidrug resistance in breast and gastric cancer models, with combination therapy reducing tumor growth by up to 70% in vitro and in vivo [83][84][85].

A 2025 study found that in pancreatic cancer models, resveratrol altered gut microbial composition to increase prostaglandin D2 (PGD2) production, amplifying the efficacy of anti-PD-1 checkpoint inhibitors by boosting CD8+ T-cell infiltration and reducing tumor burden by over 50% [86].

However, Phase I and II clinical trials have established safety at doses up to 5 g/day in cancer patients with mild gastrointestinal side effects but no severe toxicity, while showing no standalone efficacy or regulatory approval for cancer treatment [87][88]. As noted in one review: "The promising neurodegenerative and cancer chemopreventive effects of resveratrol in animal models have not been yet confirmed in humans" [89]. Because resveratrol has mild estrogenic activity, women with estrogen-sensitive cancer should consult a physician before use.

Exercise Performance

Two studies suggest resveratrol may blunt some positive effects of exercise training:

In older sedentary men: Healthy men in their sixties who were not physically active were given 250 mg/day of trans-resveratrol or placebo for 8 weeks during high-intensity exercise training (e.g., cycling). Both groups experienced improvements in athletic ability and body fat reduction. However, only the placebo group experienced a decrease in blood pressure (5 mmHg), improvements in cholesterol levels (LDL, total cholesterol/HDL ratio, and triglycerides), and a greater increase in maximal oxygen uptake. Among possible explanations, the researchers speculated that reactive oxygen species (ROS) normally formed during exercise trigger positive changes such as increased oxygen uptake, but resveratrol's antioxidant capability may remove ROS, preventing this signaling cascade [90].

In young men doing HIIT: Young men (average age 22) who performed high-intensity interval training 3 days/week for 4 weeks while taking 150 mg/day of trans-resveratrol (resVida, 99% pure, taken once daily with breakfast on non-training days and 15 minutes after exercise on training days) showed significantly less improvement in peak aerobic power and training-induced increases in skeletal muscle gene expression (including SIRT1) compared to the placebo group, leading the researchers to conclude that resveratrol may interfere with the positive effects of high-intensity exercise [91].

Liver Health (NAFLD)

In preclinical models of non-alcoholic fatty liver disease, resveratrol supplementation significantly lowered serum ALT levels by approximately 25%, alongside reductions in AST, through enhanced antioxidant enzyme activity (superoxide dismutase, catalase) and preserved hepatic glutathione levels [42]. Emerging research highlights resveratrol's role in modulating the gut-liver axis, preserving gut mucosal integrity, reducing hepatic oxidative stress, and improving lipid profiles through altered microbiota composition and enhanced bile acid metabolism [42]. In models of diabetic liver inflammation, resveratrol inhibits the NLRP3 inflammasome and associated NF-kappaB-mediated inflammation [92].

Skin Aging

Topical resveratrol formulations have shown efficacy in skin aging trials, with clinical studies reporting 10-20% reductions in wrinkle depth and improved elasticity after 4-12 weeks of application, attributed to enhanced collagen synthesis and antioxidant protection [69][70]. These effects are relevant to topical rather than oral supplementation.

Erectile Dysfunction

Preclinical studies in animal models (streptozotocin-induced diabetic rats and hypercholesterolemic rabbits) show that resveratrol promotes relaxation of corpus cavernosum tissue, improves erectile responses, and restores endothelial function through upregulation of eNOS, increased NO bioavailability, reduction of oxidative stress, and activation of SIRT1 pathways [93][94]. A small randomized, double-blind, placebo-controlled crossover pilot study found that combined supplementation with trans-resveratrol and L-citrulline significantly improved erectile function scores in men with inadequate response to PDE5 inhibitors, potentially via synergistic enhancement of the NO pathway [95]. However, studies on resveratrol monotherapy for erectile dysfunction are lacking. A randomized controlled trial in middle-aged men with metabolic syndrome reported that resveratrol reduced circulating androgen precursors but had no effect on testosterone, dihydrotestosterone, or PSA levels [96].

Antimicrobial Effects

Resveratrol disrupts biofilm development in Staphylococcus aureus at concentrations 3-4 times below its minimum inhibitory concentration. A 2025 in vitro study confirmed that resveratrol reduces S. aureus biofilm formation by up to 70% via decreased reactive oxygen species production and quorum sensing inhibition [97].

Recommended Dosing

Dosages for resveratrol of known benefit and safety in people have not been established [2]. There is no official RDA, adequate intake, or tolerable upper intake level for resveratrol.

Doses Used in Research

Clinical Context	Dose	Duration	Outcome
Calorie restriction mimicry in obese men	150 mg/day	30 days	Improved metabolic parameters [43]
Glucose metabolism + memory in overweight elderly	200 mg/day (+ 320 mg quercetin)	26 weeks	Improved memory and glucose metabolism (not replicated) [52][49]
Cognitive function in postmenopausal women	150 mg/day (75 mg twice daily)	12 months	Modest cognitive improvement [53]
Blood sugar in type 2 diabetes	40-500 mg/day	Variable	Meta-analysis suggests approximately 0.5% HbA1c reduction at approximately 500 mg/day [44]
Alzheimer's disease biomarkers	500-2,000 mg/day	12 months	Stabilized Abeta40 biomarker; no cognitive benefit [57]
Exercise training	150-250 mg/day	4-8 weeks	May blunt exercise adaptations [90][91]
Blood pressure meta-analysis	>150 mg/day	Variable	2-5 mmHg SBP reduction (inconsistent) [33]
Bone mineral density	8-1,500 mg/day	1-12 months	No significant effect [72]
Menstrual migraine	150 mg/day	3 months	No benefit [75]
COVID-19 (mild)	4,000 mg/day	7-15 days	Non-significant trend toward fewer hospitalizations [82]

Notable Researcher Dosing

Dr. David Sinclair at Harvard Medical School, a leading resveratrol researcher, has been noted as taking approximately 5 mg per kilogram of body weight per day — about 350 mg for the average adult — without notable short-term adverse effects [2].

Practical Considerations

• Evidence suggests lower doses (150-200 mg/day) may have metabolic activity while avoiding the cholesterol-raising effects seen at higher doses (500 mg/day or above) [38][39][43].
• Higher doses (500 mg/day or above) have been associated with increased total and LDL cholesterol in multiple studies [38][39] and should be used with caution.
• Very high doses (2,500-5,000 mg/day) are associated with gastrointestinal side effects including nausea, loose stools, and diarrhea [87][98].
• Resveratrol may interfere with exercise adaptations, so individuals using resveratrol during intensive training should be aware of this potential effect [90][91].
• Trans-resveratrol is the preferred form — it is more biologically active and better studied than cis-resveratrol [1][2].
• Co-administration with food containing fat may improve absorption [9][19].
• Splitting doses across the day (e.g., twice daily with meals) may help maintain more consistent plasma levels given the very short half-life of the parent compound.

Safety and Side Effects

Common Side Effects

High doses of resveratrol (2,500-5,000 mg/day) may cause mild gastrointestinal symptoms including nausea, loose stools, and diarrhea in some people [87][98]. At lower doses (up to approximately 1,000 mg/day), resveratrol is generally well tolerated, with side effects primarily limited to gastrointestinal disturbances that are dose-dependent and typically mild, resolving upon discontinuation [99]. In rats, the oral median lethal dose (LD50) exceeds 5,000 mg/kg body weight, indicating minimal acute toxicity [100].

Cholesterol Elevation

Moderately high doses of resveratrol (>500 mg/day) may cause increases in blood levels of total and LDL cholesterol [38][39]. This has been observed in at least three studies:

• 1,000 mg/day increased total and LDL cholesterol and worsened fructosamine in men with metabolic syndrome [38].
• 700 mg/day (with TA-65) significantly elevated total cholesterol (+25.3 mg/dL) and LDL cholesterol (+17.4 mg/dL) in healthy older adults, leading to premature treatment termination [39].
• Pterostilbene (100-250 mg/day) also increased total and LDL cholesterol in people with high cholesterol [26].

Estrogenic Activity

Resveratrol (particularly the trans form) has mild estrogenic activity that has not been fully evaluated in humans. It acts as a mixed agonist/antagonist for estrogen receptors (ERalpha and ERbeta), with effects depending on cellular context and co-activators present [101]. Until more is known, women with estrogen-sensitive conditions, including some cancers, should consult a physician before taking resveratrol [2].

Exercise Blunting

Resveratrol may blunt some positive effects of exercise training by scavenging reactive oxygen species that serve as signaling molecules for exercise adaptations. Two studies in men found reduced improvements in blood pressure, cholesterol, maximal oxygen uptake, and skeletal muscle gene expression when resveratrol was taken during exercise training [90][91].

Kidney Safety Concern (SRT501)

A clinical study in patients with multiple myeloma using SRT501 — a proprietary micronized resveratrol formulation with improved bioavailability (not sold as a supplement) — was suspended in 2010 due to "unexpected safety events." The problem was cast nephropathy, a type of kidney damage that can occur with multiple myeloma [21]. This appears specific to the enhanced-bioavailability formulation in a vulnerable population. The ClinicalTrials.gov posting provides details of the suspension.

Iron and Copper Effects

There is mixed evidence from laboratory and animal studies as to whether resveratrol inhibits iron absorption or decreases iron storage or blood ferritin levels [102][103][104]. One consumer reported mild anemia after supplementing with a resveratrol product containing phytates and quercetin for six months — ingredients that may independently interfere with iron absorption [2]. Resveratrol may also bind to and/or inhibit the absorption of copper, which could theoretically lead to copper deficiency, although this has not been reported in people [102].

Thyroid Effects

Laboratory and animal studies suggest resveratrol may affect thyroid function. In rats, large doses (25 mg/kg) increased TSH levels (thyroid-stimulating hormone) and caused thyroid enlargement (goiter) [105]. People with thyroid disease or those taking thyroid medication should use resveratrol with caution.

Emodin Contamination

Resveratrol derived from Japanese knotweed (Polygonum cuspidatum) that is not highly purified may contain the compound emodin. It has been suggested that emodin may have a laxative effect, but this has not been established [2].

Contraindications

• Pregnancy, nursing, or trying to conceive: Resveratrol should not be used, particularly due to potential anti-growth factor properties. Animal and primate studies indicate potential risks at high doses, including fetal abnormalities and prolonged gestation [106].
• Children: Should not use resveratrol due to potential anti-growth factor properties.
• Blood-thinning medications: Consult a physician before use (see Drug Interactions).
• Estrogen-sensitive cancers or conditions: Consult a physician before use.
• Multiple myeloma or kidney disease: Exercise particular caution given the SRT501 safety event [21].

Long-Term Safety

Short-term studies of resveratrol in healthy volunteers have shown no serious side effects. Chronic exposure data from clinical trials support safety up to 5 g/day for durations of up to 6 months, with no significant adverse events beyond transient gastrointestinal issues and no evidence of genotoxicity or carcinogenicity [87][99]. A 2024 systematic review of human intervention trials confirmed tolerability across various doses [99]. However, the long-term safety of resveratrol beyond 6 months has not been well evaluated [2].

Drug Interactions

Cytochrome P450 Inhibition

Resveratrol exhibits moderate inhibition of cytochrome P450 enzymes, notably CYP3A4 and CYP2C9, which can alter the metabolism and increase plasma concentrations of co-administered drugs that are substrates for these enzymes [107]:

Drug/Class	Enzyme Affected	Clinical Concern
Statins (simvastatin, atorvastatin)	CYP3A4	Increased statin levels may heighten risk of myopathy [107][108]
Warfarin (S-warfarin)	CYP2C9	Increased systemic exposure by approximately 49%, enhancing anticoagulant effects and prolonging prothrombin time in animal models [109]
Tacrolimus	CYP3A4	Theoretical elevation of tacrolimus levels in transplant patients, necessitating therapeutic drug monitoring [107]
Tamoxifen	Mixed ER activity	Resveratrol's mixed estrogen receptor agonist/antagonist profile may modulate tamoxifen efficacy in breast cancer treatment [101]

Whether resveratrol meaningfully interferes with drug therapies in humans has not been fully studied, and individuals taking prescription medications are advised to consult a physician before taking resveratrol because of potential drug interactions [2].

Antiplatelet and Anticoagulant Effects

Resveratrol demonstrates anti-platelet (blood-thinning) activity through peroxidase-mediated inactivation of cyclooxygenase-1 (COX-1), similar to aspirin's mechanism [110]. This creates additive bleeding risk when combined with:

• Warfarin: Enhanced anticoagulant effects through both pharmacokinetic interaction (CYP2C9 inhibition increasing warfarin levels) and pharmacodynamic interaction (antiplatelet activity) [109][110]
• Aspirin: Additive antiplatelet effects via shared COX-1 inhibition; resveratrol has been suggested as an adjunct in aspirin-resistant cases, particularly in diabetic patients, but with caution for bleeding [111]
• Clopidogrel and other antiplatelet agents: Potential synergistic inhibition of platelet aggregation, increasing bruising and hemorrhage risk [110]

Individuals taking blood-thinning medications are strongly advised to consult a physician before taking resveratrol and to monitor INR and bleeding parameters [2].

Noted Combinations

Resveratrol is often combined with coenzyme Q10 (CoQ10) in longevity protocols with no well-documented adverse interactions [112]. It may enhance the antioxidant activity of quercetin through synergistic free radical scavenging [113]. However, both resveratrol and aged garlic extract exhibit mild antiplatelet effects, which may theoretically result in additive antiplatelet activity [114].

Dietary Sources

Resveratrol occurs naturally in several foods and beverages, though concentrations are low relative to supplement doses.

Content in Foods and Beverages

Food/Beverage	Resveratrol Content	Notes
Red wine	0.1-14.3 mg/L	Primarily trans-form from grape skins; varies by grape variety and region. Approximately 0.2-2 mg per 5 oz glass [1][15]
Grape juice (red)	0.2-1.5 mg/L	Higher in red varieties; includes cis and trans isomers plus glycosides (piceid) [1]
Peanuts (raw/roasted)	0.02-1.92 mg/kg	Reduced in processed forms like peanut butter due to heat and mechanical processing [1]
Berries (blueberries, cranberries)	0.1-10 mg/kg (fresh weight)	Up to 19 mg/kg in cranberries; varies widely by species and ripeness [1]
Mulberries	Variable	Trace to moderate amounts depending on species
Cocoa powder	approximately 1.85 mg/kg	Dark chocolate: approximately 1.24 mg/kg [1]
Pistachios	approximately 1.3 mg/kg	Dehulled kernels [1]
Apples, plums	Trace amounts	Small contribution to dietary intake [1]

Dietary Intake

Typical daily dietary intake of resveratrol in Western populations ranges from 0.1-5 mg, primarily from wine and grape products. Average intakes in European cohorts were approximately 0.46 mg/day for women and 0.63 mg/day for men [1]. This is far below the doses (100-2,000 mg/day) used in clinical trials, which is why dietary intake alone is insufficient to achieve the plasma levels studied in research.

Red Wine Context

Red wine contains approximately 1-2 mg of trans-resveratrol per bottle [15]. Resveratrol supplementation has not been shown to offer the cardiovascular benefits associated with light-to-moderate alcohol consumption (about one glass of wine or pint of beer per day) [2][12]. The cardiovascular benefits of moderate alcohol consumption are likely attributable to the combined effects of ethanol and hundreds of polyphenolic compounds in wine rather than resveratrol alone. The resveratrol content of wine is far too low to achieve plasma levels used in clinical studies [1].

In red wine, resveratrol concentrations are typically low (0.2-5 mg per liter in most assessments), resulting in about 0.2-2 mg per 5 oz glass. This is insufficient to achieve the plasma levels used in animal or in vitro studies. Bioavailability is poor (low absorption, rapid metabolism to conjugates), further limiting any benefits from moderate wine intake [1].

Processing Effects on Food Content

Food processing significantly influences resveratrol levels. In winemaking, alcoholic fermentation with grape skins enhances trans-resveratrol concentration compared to white wines, where skins are removed early (resulting in levels below 2.1 mg/L). Cooking and roasting peanuts reduces resveratrol content. In grape juices, the cis-isomer often predominates alongside trans-resveratrol and its glucosides [1].

Japanese Knotweed

Japanese knotweed (Polygonum cuspidatum / Fallopia japonica) is the primary commercial source of supplemental resveratrol due to its high root concentrations. It originated in Japan and China and was introduced to the US in the late 1800s, where it is now considered invasive (it tends to crowd out other plants and its roots can damage riverbanks and building foundations). In Japan, young leaves and shoots are eaten, but amounts of resveratrol in the edible plant are much lower than in concentrated extracts. Resveratrol extracted from Japanese knotweed for supplements is likely to come from China, although there are other sources such as Canada [2].

References

[1] Grokipedia. "Resveratrol." https://grokipedia.com/page/Resveratrol

[2] ConsumerLab. "Resveratrol Supplements Review." https://www.consumerlab.com/reviews/resveratrol-review/resveratrol-red-wine/

[3] Jeandet P, Bessis R, Gautheron B. "The Production of Resveratrol (3,5,4'-trihydroxystilbene) by Grape Berries in Different Developmental Stages." *Am J Enol Vitic*. 1991;42(1):41-46.

[4] Nonomura S, Kanagawa H, Makimoto A. "Chemical Constituents of Polygonaceous Plants. I. Studies on the Components of Ko-jo-kon." *Yakugaku Zasshi*. 1963;83:988-990.

[5] Renaud S, de Lorgeril M. "Wine, alcohol, platelets, and the French paradox for coronary heart disease." *Lancet*. 1992;339(8808):1523-1526.

[6] Howitz KT, Bitterman KJ, Cohen HY, et al. "Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan." *Nature*. 2003;425(6954):191-196. https://doi.org/10.1038/nature01960

[7] Baur JA, Pearson KJ, Price NL, et al. "Resveratrol improves health and survival of mice on a high-calorie diet." *Nature*. 2006;444(7117):337-342. https://doi.org/10.1038/nature05354

[8] Walle T, Hsieh F, DeLegge MH, et al. "High absorption but very low bioavailability of oral resveratrol in humans." *Drug Metab Dispos*. 2004;32(12):1377-1382.

[9] Kapetanovic IM, Muzzio M, Huang Z, et al. "Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats." *Cancer Chemother Pharmacol*. 2011;68(3):593-601. https://doi.org/10.1007/s00280-010-1525-4

[10] Boocock DJ, Faust GE, Patel KR, et al. "Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol." *Cancer Epidemiol Biomarkers Prev*. 2007;16(6):1246-1252.

[11] Walle T. "Bioavailability of resveratrol." *Ann N Y Acad Sci*. 2011;1215:9-15.

[12] Ding C, O'Neill D, Bell S, et al. "Association of alcohol consumption with morbidity and mortality in patients with cardiovascular disease." *BMC Medicine*. 2021;19:167.

[13] Stervbo U, Vang O, Bonnesen C. "A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine." *Food Chem*. 2007;101(2):449-457.

[14] Gambini J, Ingles M, Olaso G, et al. "Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects." *Oxid Med Cell Longev*. 2015;2015:837042. https://doi.org/10.1155/2015/837042

[15] Stervbo U, Vang O, Bonnesen C. "A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine." *Food Chem*. 2006;101(2):449-457.

[16] Wenzel E, Somoza V. "Metabolism and bioavailability of trans-resveratrol." *Mol Nutr Food Res*. 2005;49(5):472-481.

[17] Jannin B, Menzel M, Berlber JP, et al. "Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake." *Biochem Pharmacol*. 2004;68(6):1113-1118.

[18] Vingtdeux V, Dreses-Werringloer U, Zhao H, et al. "Therapeutic potential of resveratrol in Alzheimer's disease." *BMC Neurosci*. 2008;9(Suppl 2):S6.

[19] Amiot MJ, Romier B, Dao TM, et al. "Optimization of trans-resveratrol bioavailability for human therapy." *Biochimie*. 2013;95(6):1233-1238.

[20] Howells LM, Berry DP, Elliott PJ, et al. "Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases." *Cancer Prev Res*. 2011;4(9):1419-1425.

[21] Smoliga JM, Baur JA, Hausenblas HA. "Resveratrol and health — a comprehensive review of human clinical trials." *Mol Nutr Food Res*. 2011;55(8):1129-1141. https://doi.org/10.1002/mnfr.201100143

[22] Pentek T, et al. "Transbuccal versus oral resveratrol administration." Data showing 15x improved bioavailability via buccal route (0.61% vs 0.04% of dose detected in blood).

[23] Liposomal resveratrol delivery systems achieving 3-8x higher systemic exposure. Reviewed in Grokipedia, 2025.

[24] Kapetanovic IM, et al. "Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats." *Cancer Chemother Pharmacol*. 2011;68(3):593-601.

[25] Pterostilbene bioavailability approximately 80% vs approximately 20% for resveratrol; half-life approximately 105 min vs approximately 14 min. Reviewed in Grokipedia, 2025.

[26] Riche DM, Riche KD, Engel SE, et al. "Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial." *Evid Based Complement Alternat Med*. 2014;2014:459165.

[27] Riche DM, McEwen CL, Riche KD, et al. "Analysis of safety from a human clinical trial with pterostilbene." *J Toxicol*. 2013;2013:463595.

[28] Piotrowska H, Kucinska M, Murias M. "Biological activity of piceatannol: leaving the shadow of resveratrol." *Mutat Res*. 2012;750(1):60-82.

[29] Piceatannol as a more effective SIRT1 activator and antioxidant. Reviewed in Grokipedia, 2025.

[30] Romero-Perez AI, et al. "Determination of Piceid and Resveratrol in Spanish Wines." *J Agric Food Chem*. 1999;47(4):1533-1536.

[31] Wallerath T, Deckert G, Ternes T, et al. "Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase." *Circulation*. 2002;106(13):1652-1658.

[32] Fujitaka K, Otani H, Jo F, et al. "Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment." *Nutr Res*. 2011;31(11):842-847.

[33] Liu Y, Ma W, Zhang P, et al. "Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials." *Clin Nutr*. 2015;34(1):27-34.

[34] Resveratrol supplementation: a therapeutic potential for cardiac remodeling in hypertension. Systematic review, 2023.

[35] de Ligt M, Bruls YMH, Hansen J, et al. "Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue." *Am J Clin Nutr*. 2020;112(2):318-328.

[36] Bo S, Ponzo V, Ciccone G, et al. "Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients." *Pharmacol Res*. 2016;111:896-905.

[37] Poulsen MM, Vestergaard PF, Clasen BF, et al. "High-dose resveratrol supplementation in obese men." *Diabetes*. 2013;62(4):1186-1195.

[38] Kjaer TN, Ornstrup MJ, Poulsen MM, et al. "No beneficial effects of resveratrol on the metabolic syndrome." *J Clin Endocrinol Metab*. 2017;102(5):1642-1651.

[39] Muscari A, Spiller I, Bianchi G, et al. "Resveratrol and TA-65 supplementation in community-dwelling healthy older adults." *Geroscience*. 2025. https://doi.org/10.1007/s11357-024-01473-8

[40] Wilson T, Knight TJ, Beitz DC, et al. "Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits." *Life Sci*. 1996;59(1):PL15-21.

[41] Tome-Carneiro J, Gonzalvez M, Larrosa M, et al. "Resveratrol in primary and secondary prevention of cardiovascular disease." *Ann N Y Acad Sci*. 2013;1290:37-51.

[42] Resveratrol attenuates hepatic oxidative stress and preserves gut mucosal integrity in NAFLD models. 2025. Reviewed in Grokipedia.

[43] Timmers S, Konings E, de Vos WM, et al. "Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans." *Cell Metab*. 2011;14(5):612-622.

[44] Meta-analysis data indicating resveratrol at approximately 500 mg/day reduces HbA1c by approximately 0.5% in type 2 diabetes. Systematic review and meta-analysis, 2021.

[45] Updated meta-analysis confirming dose-dependent glycemic benefits. 2022.

[46] AMPK activation by resveratrol enhancing GLUT4 translocation and glucose uptake. Reviewed in Grokipedia, 2025.

[47] Resveratrol modulates adipokine profiles (decreasing leptin, increasing adiponectin) and protects pancreatic beta-cells. Reviewed in Grokipedia, 2025.

[48] Resveratrol activates SIRT1 influencing metabolic gene expression. Reviewed in Grokipedia, 2025.

[49] Huhn S, Beyer F, Zhang R, et al. "Effects of resveratrol plus vitamin D on memory and hippocampal connectivity in overweight older adults." *Neuroimage*. 2018;174:177-190.

[50] Gut microbiota modulation by resveratrol in obesity models; 5-10% body weight reduction via enhanced microbial diversity. 2025 preclinical data. Reviewed in Grokipedia.

[51] Meta-analysis of 32 RCTs on resveratrol and renal function (decreased BUN, creatinine; increased GFR). Systematic review, 2023.

[52] Witte AV, Kerti L, Margulies DS, Floel A. "Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults." *J Neurosci*. 2014;34(23):7862-7870. https://doi.org/10.1523/JNEUROSCI.0385-14.2014

[53] Zaw T, Howe PR, Wong RH. "Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women." *Nutrients*. 2020;12(3):828.

[54] Kennedy DO, Wightman EL, Reay JL, et al. "Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans." *Am J Clin Nutr*. 2010;91(6):1590-1597. https://doi.org/10.3945/ajcn.2009.28641

[55] Wong RH, Berry NM, Coates AM, et al. "Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults." *J Hypertens*. 2013;31(9):1819-1827.

[56] Resveratrol 250 mg restores neurovascular coupling after acute sleep restriction. 2025 study. Reviewed in Grokipedia.

[57] Turner RS, Thomas RG, Craft S, et al. "A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease." *Neurology*. 2015;85(16):1383-1391. https://doi.org/10.1212/WNL.0000000000002035

[58] Resveratrol promotes clearance of amyloid-beta via autophagy activation and inhibits tau hyperphosphorylation. Preclinical data. Reviewed in Grokipedia, 2025.

[59] Moussa C, Hebron M, Huang X, et al. "Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease." *J Neuroinflammation*. 2017;14(1):1.

[60] 2023 meta-analysis indicating cognitive function enhancements and trends toward better MMSE scores. Reviewed in Grokipedia.

[61] Resveratrol in rodent models of Parkinson's disease: protection of dopaminergic neurons. Reviewed in Grokipedia, 2025.

[62] ERK activation by resveratrol in Huntington's disease models. Reviewed in Grokipedia, 2025.

[63] Li Y, Xu W, McBurney MW, Bhatt H. "SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons." *Acta Biochim Biophys Sin*. 2013;45(11):929-936.

[64] Hubbard BP, Gomes AP, Dai H, et al. "Evidence for a common mechanism of SIRT1 regulation by allosteric activators." *Science*. 2013;339(6124):1216-1219. https://doi.org/10.1126/science.1231097

[65] Nrf2 pathway upregulation by resveratrol. Reviewed in Grokipedia, 2025.

[66] NF-kappaB pathway inhibition by resveratrol. Reviewed in Grokipedia, 2025.

[67] Valenzano DR, Terzibasi E, Genade T, et al. "Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate." *Curr Biol*. 2006;16(3):296-300.

[68] Lifespan extension in nematodes and fruit flies (20-30%). Reviewed in Grokipedia, 2025.

[69] Reviews from 2024-2025 on senescence markers and topical skin aging effects. Reviewed in Grokipedia.

[70] Topical resveratrol: 10-20% wrinkle depth reduction and improved elasticity in clinical studies. Reviewed in Grokipedia, 2025.

[71] Calabrese EJ, Mattson MP, Calabrese V. "Resveratrol commonly displays hormesis." *Hum Exp Toxicol*. 2010;29(12):980-1015. https://pubmed.ncbi.nlm.nih.gov/20488844/

[72] Li J, Gong H, Liu R. "Effects of resveratrol on bone mineral density: a meta-analysis of randomized controlled trials." *BMC Complement Med Ther*. 2021;21:271.

[73] Wong G, Mah K, Wong RH. "Effects of resveratrol on bone health in postmenopausal women with osteopenia." *J Bone Miner Res*. 2020;35(11):2139-2147.

[74] Zaw T, Howe PR, Wong RH. "Postmenopausal health interventions." *Menopause*. 2020;27(10):1101-1108.

[75] Dzator JSA, Howe PR, Wong RH. "Profiling the effects of resveratrol on menstrual migraine." *Nutrients*. 2022;14(9):1872.

[76] Nagineni CN, Raju R, Nagineni KK, et al. "Resveratrol suppresses expression of VEGF by human retinal pigment epithelial cells." *Aging Dis*. 2014;5(2):88-100.

[77] Richer S, Stiles W, Thomas C. "Molecular medicine in optic nerve disease." *Optometry*. 2009;80(12):714-716.

[78] Richer S, Stiles W, Ulanski L, et al. "Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement." *Nutrients*. 2013;5(6):1989-2005.

[79] Richer S, Patel S, Engel-Britt S, et al. "Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation." *Nutrients*. 2014;6(3):1177-1201.

[80] Wang S, Wang B, Bhatt D, et al. "Effects of resveratrol on choroidal thickness." *Curr Eye Res*. 2016;41(12):1575-1578.

[81] Abba Y, Hassim H, Hamzah H, et al. "Antiviral activity of resveratrol against human and animal viruses." *Adv Virol*. 2015;2015:184241.

[82] McCreary MR, Schnell PM, Rhoda DA. "Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)." *Sci Rep*. 2022;12(1):10978.

[83] Jang M, Cai L, Udeani GO, et al. "Cancer chemopreventive activity of resveratrol." *Science*. 1997;275(5297):218-220. Preclinical data on IC50 values and multiple cancer types. Reviewed in Grokipedia, 2025.

[84] Resveratrol synergy with doxorubicin in overcoming multidrug resistance. Reviewed in Grokipedia, 2025.

[85] Resveratrol promotes sensitization to doxorubicin by inhibiting epithelial-mesenchymal transition. Reviewed in Grokipedia, 2025.

[86] Resveratrol amplifies anti-tumor effect of anti-PD-1 by altering gut microbiome composition. 2025. Reviewed in Grokipedia.

[87] Brown VA, Patel KR, Viskaduraki M, et al. "Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers." *Cancer Res*. 2010;70(22):9003-9011.

[88] Patel KR, Brown VA, Jones DJ, et al. "Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients." *Cancer Res*. 2010;70(19):7392-7399.

[89] Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, et al. "Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence." *Curr Pharm Des*. 2013;19(34):6064-6093.

[90] Gliemann L, Schmidt JF, Olesen J, et al. "Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men." *J Physiol*. 2013;591(20):5047-5059.

[91] Scribbans TD, Ma JK, Edgett BA, et al. "Resveratrol supplementation does not augment performance adaptations or fibre-type-specific responses to high-intensity interval training in humans." *Appl Physiol Nutr Metab*. 2014;39(11):1305-1313.

[92] NLRP3 inflammasome inhibition by resveratrol in diabetic liver inflammation models. Reviewed in Grokipedia, 2025.

[93] Resveratrol restores erectile function in streptozotocin-induced diabetic rats via SIRT1 activation. Reviewed in Grokipedia.

[94] Efficacy of resveratrol in male urogenital tract dysfunctions: preclinical evaluation. Reviewed in Grokipedia.

[95] Oral L-citrulline and trans-resveratrol supplementation improves erectile function in men with PDE5 inhibitor inadequate response. Reviewed in Grokipedia.

[96] Resveratrol reduces circulating androgen precursors but has no effect on testosterone, DHT, or PSA. Reviewed in Grokipedia.

[97] Resveratrol inhibits S. aureus biofilm formation by up to 70%. 2025 in vitro study. Reviewed in Grokipedia.

[98] Chachay VS, Macdonald GA, Martin JH, et al. "Resveratrol does not benefit patients with nonalcoholic fatty liver disease." *Clin Gastroenterol Hepatol*. 2014;12(12):2092-2103.

[99] 2024 systematic review of human intervention trials confirming tolerability across various doses. Reviewed in Grokipedia.

[100] Oral LD50 in rats exceeds 5,000 mg/kg body weight. Reviewed in Grokipedia, 2025.

[101] Resveratrol acts as a mixed agonist/antagonist for estrogen receptors (ERalpha and ERbeta). Reviewed in Grokipedia, 2025.

[102] Belguendouz L, Fremont L, Linard A. "Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins." *Biochem Pharmacol*. 1997;53(9):1347-1355.

[103] Horn P, et al. "Effects of resveratrol on iron metabolism." *Food Chem Toxicol*. 2007;45(7):1123-1129.

[104] Li R, et al. "Resveratrol and iron metabolism." *Toxicol Appl Pharmacol*. 2021;425:115614.

[105] Giuliani C, Bucci I, Di Santo S, et al. "Resveratrol and thyroid function." *Food Chem Toxicol*. 2017;107(Pt A):67-73.

[106] Roberts VH, Pound LD, Thorn SR, et al. "Beneficial and cautionary outcomes of resveratrol supplementation in pregnant nonhuman primates." *FASEB J*. 2014;28(6):2466-2477.

[107] Chow HH, Garland LL, Hsu CH, et al. "Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study." *Cancer Prev Res*. 2010;3(9):1168-1175.

[108] Dietary modulation of CYP3A4 and its impact on statins. Reviewed in Grokipedia, 2025.

[109] Hong SP, Choi DH, Choi JS. "Effects of resveratrol on the pharmacokinetics of warfarin enantiomers in rats." *J Pharm Pharmacol*. 2008;60(11):1459-1463.

[110] Szewczuk LM, Forti L, Stivala LA, Penning TM. "Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2." *J Nat Prod*. 2004;67(1):36-42.

[111] Resveratrol as a potential platelet inhibitor in aspirin-resistant diabetic patients. Reviewed in Grokipedia, 2025.

[112] Resveratrol and CoQ10 combination: no well-documented adverse interactions. Reviewed in Grokipedia, 2025.

[113] Antioxidant synergy of trans-resveratrol, pterostilbene, and quercetin. Reviewed in Grokipedia, 2025.

[114] Aged garlic extract exhibits mild antiplatelet effects; theoretical additive activity with resveratrol. Reviewed in Grokipedia, 2025.